Murphy earned his undergraduate degree in medicine at University College Cork (UCC), graduating in 1973. He undertook further studies at the
Royal Postgraduate Medical School in London, England. He then studied for a doctorate at the
National University of Ireland, which he completed in 1984.[5]
Career
From 1984 to 1992, Murphy taught medicine and pharmacology at the
University of Chicago in the United States.[5] In 1992, he returned to Ireland and UCC, where he had been appointed
Professor of Clinical Pharmacology and Therapeutics.[5] He was appointed the dean of the faculty of medicine and health at UCC in 2000, before becoming the head of its college of medicine and health in 2006.[6] In December 2006, he was announced as the next President of University College Cork.[6] He took up the post on 1 February 2007 in succession to Gerry Wrixon.[7] He stepped down as president in 2017, after ten years leading UCC, and was succeeded by
Patrick O'Shea.[8]
Wood, Alastair J.J.; Murphy, Michael B.; Murray, Clare; Shorten, George D. (22 November 2001). "Fenoldopam – A Selective Peripheral Dopamine-Receptor Agonist for the Treatment of Severe Hypertension". New England Journal of Medicine. 345 (21): 1548–1557.
doi:
10.1056/NEJMra010253.
PMID11794223.
Shepherd, James; Blauw, Gerard J; Murphy, Michael B; Bollen, Edward LEM; Buckley, Brendan M; Cobbe, Stuart M; Ford, Ian; Gaw, Allan; Hyland, Michael; Jukema, J Wouter; Kamper, Adriaan M; Macfarlane, Peter W; Meinders, A Edo; Norrie, John; Packard, Chris J; Perry, Ivan J; Stott, David J; Sweeney, Brian J; Twomey, Gillian; Westendorp, Rudi GJ (November 2002). "Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial". The Lancet. 360 (9346): 1623–1630.
doi:
10.1016/S0140-6736(02)11600-X.
PMID12457784.
S2CID5261493.
Kearney, PM; Blackwell, L; Collins, R; Keech, A; Simes, J; Peto, R; Armitage, J; Baigent, C (January 2008). "Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis". The Lancet. 371 (9607): 117–125.
doi:
10.1016/S0140-6736(08)60104-X.
PMID18191683.
S2CID139647531.
Sattar, Naveed; McConnachie, Alex; Shaper, A Gerald; Blauw, Gerard J; Buckley, Brendan M; de Craen, Anton J; Ford, Ian;
Forouhi, Nita G; Freeman, Dilys J; Jukema, J Wouter; Lennon, Lucy; Macfarlane, Peter W; Murphy, Michael B; Packard, Chris J; Stott, David J; Westendorp, Rudi G; Whincup, Peter H; Shepherd, James; Wannamethee, S Goya (June 2008). "Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies". The Lancet. 371 (9628): 1927–1935.
doi:
10.1016/S0140-6736(08)60602-9.
PMID18501419.
S2CID14858094.